TScan Therapeutics, Inc.
TCRX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001783328
No open-market purchases or sales by TScan Therapeutics, Inc. insiders were filed in the last 90 days; 60 institutions reported holding it in 13F filings for Q2 2026, worth $35.1M in total; no superinvestor holds it.
Q2 2022 vs. Q1 2022
How the institutions holding TScan Therapeutics, Inc. changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Q2 2022 | Change |
|---|---|---|---|
| Holders | 25 | 24 | −1 |
| Shares | 9.41M | 9.68M | +274.4K (+2.9%) |
| Value | $26.3M | $30.4M | +$4.11M (+15.6%) |
New holders (6)
Institutions that held TScan Therapeutics, Inc. at the end of Q2 2022 but not at the end of Q1 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Newtyn Management, LLC | 248,611 | $782.0K | 0.15% |
| LPL Financial LLC | 16,000 | $50.0K | 0.00% |
| Jane Street Group, LLC | 10,176 | $32.0K | 0.00% |
| Cannell Capital LLC | 3,654 | $11.0K | 0.00% |
| UBS Group AG | 1,148 | $4.00K | 0.00% |
| Atlas Capital Advisors LLC | 896 | $2.82K | 0.00% |
Sold out (7)
Institutions that held TScan Therapeutics, Inc. at the end of Q1 2022 and filed for Q2 2022 without it.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Ra Capital Management, L.P. | 1,021,764 | $2.86M |
| HHLR Advisors, Ltd.SuperinvestorHHLR Advisors (Hillhouse) | 669,513 | $1.88M |
| Barclays PLC | 158,944 | $445.0K |
| Norges Bank | 60,000 | $168.0K |
| Renaissance Technologies LLC | 13,300 | $37.0K |
| Royal Bank of Canada | 1,000 | $3.00K |
| JPMorgan Chase & Co | 361 | $1.00K |